Global Proto-Oncogene Drgu Market By Product Type (Axitinib (Inlyta), Ponatinib (Iclusig)) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-985156
  • April 2021
  • Pharmaceuticals
  • 119 Pages

Report Preview

The Proto-Oncogene Drgu market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Proto-Oncogene Drgu market research report recommends a business strategy for present market participants to strengthen their position in the market.

According to the report, the Proto-Oncogene Drgu market size was USD xx million and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2020-2028. While considering the volume shipments the global Proto-Oncogene Drgu market stood at xx (Units/Tons) in 2020 and expected to cross near about xx (units/Tons) by the end of forecast period.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Proto-Oncogene Drgu market along with their effects over the forecast period. Similarly, according to the region Proto-Oncogene Drgu market research report includes the study of opportunities available in the market situation.

The Proto-Oncogene Drgu market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Axitinib (Inlyta), Ponatinib (Iclusig), Imatinib (Gleevec), Sunitinib (Sutent), Pazopanib (Votrient), Dabrafenib (Tafinlar), Vandetanib (Caprelsa), Vemurafenib (Zelboraf), Cabozantinib (Cabometyx and Cometriq), Sorafenib (Nexavar)
Applications Clinic, Hospital, Others
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, Pfizer

Global Proto-Oncogene Drgu Market Segmentation by Regions:
In regional analysis, Proto-Oncogene Drgu market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Proto-Oncogene Drgu market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Proto-Oncogene Drgu Market: Value and Forecast
  • U.S.
  • Canada
 
Europe Region for Proto-Oncogene Drgu Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 
Asia Pacific Region for Proto-Oncogene Drgu Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 
Latin America Region for Proto-Oncogene Drgu Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 
Middle East and Africa for Proto-Oncogene Drgu Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Global Proto-Oncogene Drgu Market Segmentation by Type:
On the basis of product type, global Proto-Oncogene Drgu market research report provides the production, revenue, price, and market share and growth rate of each type, primarily split into: Axitinib (Inlyta), Ponatinib (Iclusig), Imatinib (Gleevec), Sunitinib (Sutent), Pazopanib (Votrient), Dabrafenib (Tafinlar), Vandetanib (Caprelsa), Vemurafenib (Zelboraf), Cabozantinib (Cabometyx and Cometriq), Sorafenib (Nexavar)

Global Proto-Oncogene Drgu Market Segmentation by Applications:
On the basis of the end users/applications, Proto-Oncogene Drgu research report analyze the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including: Clinic, Hospital, Others

Major Key Players for Global Proto-Oncogene Drgu Market:
The Proto-Oncogene Drgu market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, Pfizer

Important Points Covered by Report:
  • To analyze the value of the Proto-Oncogene Drgu market, according to the key region.
  • To study the Proto-Oncogene Drgu market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Proto-Oncogene Drgu market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Proto-Oncogene Drgu research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Proto-Oncogene Drgu market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Proto-Oncogene Drgu market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Proto-Oncogene Drgu market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Proto-Oncogene Drgu market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Proto-Oncogene Drgu market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • ARIAD Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • ChemGenex Pharmaceuticals
  • Dexa Medica
  • Eisai Pharmaceuticals
  • Exelixis
  • GlaxoSmithKline
  • Novartis
  • Onyx Pharmaceuticals
  • Plexxikon
  • Pfizer
  • Axitinib (Inlyta)
  • Ponatinib (Iclusig)
  • Imatinib (Gleevec)
  • Sunitinib (Sutent)
  • Pazopanib (Votrient)
  • Dabrafenib (Tafinlar)
  • Vandetanib (Caprelsa)
  • Vemurafenib (Zelboraf)
  • Cabozantinib (Cabometyx and Cometriq)
  • Sorafenib (Nexavar)
  • Clinic
  • Hospital
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Proto-Oncogene Drgu Market Snapshot
          2.1.1. Global Proto-Oncogene Drgu Market By Type,2019
               2.1.1.1.Axitinib (Inlyta)
               2.1.1.2.Ponatinib (Iclusig)
               2.1.1.3.Imatinib (Gleevec)
               2.1.1.4.Sunitinib (Sutent)
               2.1.1.5.Pazopanib (Votrient)
               2.1.1.6.Dabrafenib (Tafinlar)
               2.1.1.7.Vandetanib (Caprelsa)
               2.1.1.8.Vemurafenib (Zelboraf)
               2.1.1.9.Cabozantinib (Cabometyx and Cometriq)
               2.1.1.10.Sorafenib (Nexavar)
          2.1.2. Global Proto-Oncogene Drgu Market By Application,2019
               2.1.2.1.Clinic
               2.1.2.2.Hospital
               2.1.2.3.Others
          2.1.3. Global Proto-Oncogene Drgu Market By End-use,2019
          2.1.4. Global Proto-Oncogene Drgu Market By Geography,2019

3. Global Proto-Oncogene Drgu Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028

5. Global Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028

6. Global Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028

7. Global Proto-Oncogene Drgu Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Proto-Oncogene Drgu Market Analysis, 2018 – 2028 
          7.2.1. North America Proto-Oncogene Drgu Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Proto-Oncogene Drgu Market Analysis, 2018 – 2028 
          7.3.1.  Europe Proto-Oncogene Drgu Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Proto-Oncogene Drgu Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Proto-Oncogene Drgu Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Proto-Oncogene Drgu Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Proto-Oncogene Drgu Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Proto-Oncogene Drgu Market Analysis, 2018 – 2028 
          7.6.1.  MEA Proto-Oncogene Drgu Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Proto-Oncogene Drgu Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Proto-Oncogene Drgu Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Proto-Oncogene Drgu Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Proto-Oncogene Drgu Providers
        8.4.1 ARIAD Pharmaceuticals
                8.1.1 Business Description
                8.1.2 ARIAD Pharmaceuticals Geographic Operations
                8.1.3 ARIAD Pharmaceuticals Financial Information
                8.1.4 ARIAD Pharmaceuticals Product Positions/Portfolio
                8.1.5 ARIAD Pharmaceuticals Key Developments
        8.4.2 AstraZeneca
                8.2.1 Business Description
                8.2.2 AstraZeneca Geographic Operations
                8.2.3 AstraZeneca Financial Information
                8.2.4 AstraZeneca Product Positions/Portfolio
                8.2.5 AstraZeneca Key Developments
        8.4.3 Bayer Healthcare
                8.3.1 Business Description
                8.3.2 Bayer Healthcare Geographic Operations
                8.3.3 Bayer Healthcare Financial Information
                8.3.4 Bayer Healthcare Product Positions/Portfolio
                8.3.5 Bayer Healthcare Key Developments
        8.4.4 Bristol-Myers Squibb
                8.4.1 Business Description
                8.4.2 Bristol-Myers Squibb Geographic Operations
                8.4.3 Bristol-Myers Squibb Financial Information
                8.4.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.4.5 Bristol-Myers Squibb Key Developments
        8.4.5 ChemGenex Pharmaceuticals
                8.5.1 Business Description
                8.5.2 ChemGenex Pharmaceuticals Geographic Operations
                8.5.3 ChemGenex Pharmaceuticals Financial Information
                8.5.4 ChemGenex Pharmaceuticals Product Positions/Portfolio
                8.5.5 ChemGenex Pharmaceuticals Key Developments
        8.4.6 Dexa Medica
                8.6.1 Business Description
                8.6.2 Dexa Medica Geographic Operations
                8.6.3 Dexa Medica Financial Information
                8.6.4 Dexa Medica Product Positions/Portfolio
                8.6.5 Dexa Medica Key Developments
        8.4.7 Eisai Pharmaceuticals
                8.7.1 Business Description
                8.7.2 Eisai Pharmaceuticals Geographic Operations
                8.7.3 Eisai Pharmaceuticals Financial Information
                8.7.4 Eisai Pharmaceuticals Product Positions/Portfolio
                8.7.5 Eisai Pharmaceuticals Key Developments
        8.4.8 Exelixis
                8.8.1 Business Description
                8.8.2 Exelixis Geographic Operations
                8.8.3 Exelixis Financial Information
                8.8.4 Exelixis Product Positions/Portfolio
                8.8.5 Exelixis Key Developments
        8.4.9 GlaxoSmithKline
                8.9.1 Business Description
                8.9.2 GlaxoSmithKline Geographic Operations
                8.9.3 GlaxoSmithKline Financial Information
                8.9.4 GlaxoSmithKline Product Positions/Portfolio
                8.9.5 GlaxoSmithKline Key Developments
        8.4.10 Novartis
                8.10.1 Business Description
                8.10.2 Novartis Geographic Operations
                8.10.3 Novartis Financial Information
                8.10.4 Novartis Product Positions/Portfolio
                8.10.5 Novartis Key Developments
        8.4.11 Onyx Pharmaceuticals
                8.11.1 Business Description
                8.11.2 Onyx Pharmaceuticals Geographic Operations
                8.11.3 Onyx Pharmaceuticals Financial Information
                8.11.4 Onyx Pharmaceuticals Product Positions/Portfolio
                8.11.5 Onyx Pharmaceuticals Key Developments
        8.4.12 Plexxikon
                8.12.1 Business Description
                8.12.2 Plexxikon Geographic Operations
                8.12.3 Plexxikon Financial Information
                8.12.4 Plexxikon Product Positions/Portfolio
                8.12.5 Plexxikon Key Developments
        8.4.13 Pfizer
                8.13.1 Business Description
                8.13.2 Pfizer Geographic Operations
                8.13.3 Pfizer Financial Information
                8.13.4 Pfizer Product Positions/Portfolio
                8.13.5 Pfizer Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Proto-Oncogene Drgu Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Proto-Oncogene Drgu Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Proto-Oncogene Drgu Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Proto-Oncogene Drgu Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Proto-Oncogene Drgu Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Proto-Oncogene Drgu Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Proto-Oncogene Drgu Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Proto-Oncogene Drgu Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Proto-Oncogene Drgu Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Proto-Oncogene Drgu Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Proto-Oncogene Drgu Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Proto-Oncogene Drgu Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Proto-Oncogene Drgu Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Proto-Oncogene Drgu Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Proto-Oncogene Drgu Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Proto-Oncogene Drgu Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Proto-Oncogene Drgu: Market Segmentation 
FIG. 2 Global Proto-Oncogene Drgu Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Proto-Oncogene Drgu Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Proto-Oncogene Drgu Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Proto-Oncogene Drgu Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Proto-Oncogene Drgu Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Proto-Oncogene Drgu Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Proto-Oncogene Drgu Providers, 2019
FIG. 11 Global Proto-Oncogene Drgu Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Proto-Oncogene Drgu Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Proto-Oncogene Drgu Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Proto-Oncogene Drgu Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Proto-Oncogene Drgu Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Proto-Oncogene Drgu Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Proto-Oncogene Drgu Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Proto-Oncogene Drgu Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Proto-Oncogene Drgu market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Proto-Oncogene Drgu Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Proto-Oncogene Drgu Market Value, By Segment1, 2018 – 2028
TABLE  North America Proto-Oncogene Drgu Market Value, By Segment2, 2018 – 2028
TABLE  North America Proto-Oncogene Drgu Market Value, By Country, 2018 – 2028
TABLE  Europe Proto-Oncogene Drgu Market Value, By Segment1, 2018 – 2028
TABLE  Europe Proto-Oncogene Drgu Market Value, By Segment2, 2018 – 2028
TABLE  Europe Proto-Oncogene Drgu Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Proto-Oncogene Drgu Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Proto-Oncogene Drgu Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Proto-Oncogene Drgu Market Value, By Country, 2018 – 2028
TABLE  Latin America Proto-Oncogene Drgu Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Proto-Oncogene Drgu Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Proto-Oncogene Drgu Market Value, By Country, 2018 – 2028
TABLE  MEA Proto-Oncogene Drgu Market Value, By Segment1, 2018 – 2028
TABLE  MEA Proto-Oncogene Drgu Market Value, By Segment2, 2018 – 2028
TABLE  MEA Proto-Oncogene Drgu Market Value, By Country, 2018 – 2028
TABLE  ARIAD Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bayer Healthcare: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ChemGenex Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Dexa Medica: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eisai Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Exelixis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Onyx Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Plexxikon: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Proto-Oncogene Drgu Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Proto-Oncogene Drgu Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Proto-Oncogene Drgu Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Proto-Oncogene Drgu Market, By Geography, 2019 (US$ Mn)
FIG.  Global Proto-Oncogene Drgu Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Proto-Oncogene Drgu Providers, 2016
FIG.  Global Proto-Oncogene Drgu Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Axitinib (Inlyta) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ponatinib (Iclusig) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Imatinib (Gleevec) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Sunitinib (Sutent) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Pazopanib (Votrient) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Dabrafenib (Tafinlar) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Vandetanib (Caprelsa) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Vemurafenib (Zelboraf) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Cabozantinib (Cabometyx and Cometriq) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Sorafenib (Nexavar) Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Proto-Oncogene Drgu Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Proto-Oncogene Drgu Market Value, 2018 – 2028, (US$ Mn)